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Abstract
Background : Activation of the ras genes or association with human papillomavirus infection have
been extensively studied in colorectal cancer. However, the correlation between K-ras mutations
and HPV in colorectal cancer has not been investigated yet. In this study we aimed to investigate
the presence of K-ras mutations and their correlation with HPV infection in colon cancer.
Methods : K-ras mutations were analyzed by a mutagenic PCR assay and digestion with specific
restriction enzymes to distinguish the wild-type and mutant codons. HPV infection was analyzed by
PCR amplification and hybridization with specific probes by Southern blotting. Stattistical analyses
were performed by the chi-square and Fisher's exact tests
Results : HPV gene fragments were detected in 43 tumors and 17 normal tissue samples. HPV 18
was the prevalent type in the tumor tissue. A mutation at codon 12 of the K-ras gene was present
in 31 patients. 56% of the HPV-positive tumors also harbored a K-ras mutation. Codon 13
mutations were not observed. These data indicate that infection with high risk HPV types and
mutational activation of the K-ras gene are frequent events in colorectal carcinogenesis.
Conclusion : Our findings suggest that mutational activation of the K-ras gene is a common event
in colon carcinogenesis and that HPV infection may represent an important factor in the
development of the premalignant lesions leading to the neoplastic phenotype.
Background
Colorectal carcinogenesis is a complex, multistep process
involving environmental and lifestyle factors, sequential
genetic changes and possibly viral components in discrete
geographical areas. Genetic changes inactivating tumor
suppressor and mismatch repair genes or activation of
oncogenes which are involved in cell growth, prolifera-
tion and differentiation are implicated in the develop-
ment of colon carcinoma. The target genes for these
alterations are APC (Adenomatous Polyposis Coli), the
ras family and p53 [1]. The ras family of oncogenes (N-
ras, H-ras and K-ras) encode a small 21-kD protein (p21
ras) involved in the transduction of external stimuli to
effector molecules across plasma membranes [2]. This
protein has an intrinsic GTPase activity allowing inactiva-
tion following signal transduction in the normal cellular
environment [2,3]. Activation of the K-ras protooncogene
by point mutation is one of the most frequent genetic
alterations associated with human cancers [4,5]. Mutated
ras p21 has a structure that disfavors its ability to bind the
GTPase activating protein (GAP), thus keeping the p21 in
the GTP-bound, activated state [6]. Approximately, 90 %
of these activating mutations occur in codons 12 and 13
of exon 1 identifying these codons as hot-spot targets [7].
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The incidence of ras gene mutations, however, varies con-
siderably among different types of cancer and the profile
of ras oncogene activation is often specific for each tumor
type. For example, K-ras mutations are the predominant
ras mutation found in pancreatic cancer [8,9], N-ras muta-
tions predominate in acute myeloid leukemias [10], and
H-ras mutations, which are generally rare, are most fre-
quently observed in bladder cancer [11]. Oncogenic
mutations of K-ras are involved in 20–50 % of sporadic
colorectal carcinomas [12-14].
The association between human papillomavirus (HPV)
infection and the development of cervical and anogenital
tumors is widely accepted. However, the relationship
between human papilloma viruses and malignant die-
sases at various body sites, including the upper respiratory
and digestive tracts and the breast is still not clear [15-17].
HPV types 16 and 18 have been associated with a higher
oncogenic potential and are considered as "high risk"
types. The "low risk" HPV types HPV-6 and HPV-11 are
predominantly associated with benign mucosal lesions of
the genital tract and rarely result in invasive tumors
[15,18]. The oncogenic HPV gene product E6 promotes
degredation of the p53 tumor suppressor protein, whereas
the E7 protein inactivates the Rb protein and related
pocket proteins [19,20]. However, the tumorigenic prop-
erties of the E6 and E7 proteins may not necessarily be
limited only to the Rb and p53-related pathways [21,22].
The presence of HPV infection alone also is not sufficient
to cause tumorigenesis and requires additional cellular
modifications such as alterations in the p53 and K-ras
genes.
Although the role and distribution of K-ras mutations in
colon cancer has been studied extensively there are no
reports in the literature investigating the K-ras mutation
status in HPV-associated colorectal cancer. The present
study was undertaken to investigate the role of K-ras
codon 12 and codon 13 mutations in HPV-associated
colon tumors.
Methods
Tumor samples were obtained at the time of surgery from
53 patients with colon cancer. The corresponding normal
tissues surrounding the tumors were also analyzed. The
study was approved by the Institutional Ethics Commit-
tee. Genomic DNA was extracted from the tumors and
corresponding normal colon tissue samples by phenol/
chloroform extraction. To detect K-ras codon 12 and 13
mutations, DNA was amplified by a mutagenic PCR assay.
A mismatched upstream primer for codon 12 and a mis-
matched downstream primer for codon 13 which intro-
duced a Bst N1 (codon 12) and a HaeIII (codon 13)
restriction site in the wild type allele, respectively, were
used for amplification as described previously [23]. The
PCR reactions were carried out in a total volume of 25 µl
containing 200 ng of genomic DNA, 50 mM KCl, 1.5 mM
MgCl2, 10 pmol each of the forward and reverse primers,
1U Taq polymerase (MBI, Fermentas, Lithuania), 200 µM
dNTP mix and 20 mM Tris-HCl, pH 8.3. The reaction mix-
ture was heated to 95°C for 5 min. for initial denatura-
tion, followed by 35 cycles of denaturation at 95°C for 1
min., annealing at 60°C for 1 min. and extension at 72°C
for 1 min. Final extension was allowed to proceed for 6
min. at 72°C.
Digestion was performed in a total volume of 25 µl con-
taining 10 µl PCR product, 2.5 µl 10x digestion buffer, 5
µg BSA and 10 U of Bst N1 or HaeIII by overnight incuba-
tion at 60°C or 37°C, respectively. The digested products
were separated by 8% non-denaturing polyacrylamide gel
electrophoresis at 120 V for 3 h, the gel was stained with
ethidium bromide and the genotypes were determined
using a video gel documentation system (Vilber-Lourmat,
Marne-La-Vallée, France).
To investigate the HPV infection specific regions from the
HPV genome were amplified by the MY 09 and MY 11
consensus primers which amplify a region of about 450
bp from the L1 open reading frame. DNA from a HPV-
positive patient with cervix cancer was used as the positive
control and DNA from lymphocytes were used as the neg-
ative control. The PCR reaction mix contained 500 mM
KCl, 100 mM Tris-HCl, pH 9.0, 3 mM MgCl2, 200 µM of
each dNTP, 150 ng sample DNA, 25 pmol of each primer
and 2.5 U Taq polymerase. The reaction was begun by
incubation at 95°C for five minutes followed by 35 cycles
of denaturation at 95°C for 30 seconds, annealing at
55°C for 30 seconds and extension at 72°C for 1 minute.
30 µl of the PCR product was separated on a 1.5 % agarose
gel and the DNA samples were blotted onto positive-
charged nylon membranes (Boehringer Manheim, Ger-
many). The probes used in the study were cloned into the
pBR322 plasmid. They were separated from the vector by
digestion with Bam H1 and Eco RI for HPV16 and HPV18,
respectively. The probes were non-radioactively labeled at
their 3'-end by incorporation of digoxigenin-labeled dide-
oxyuridine-triphosphate (DIG-ddUTP). Hybridization
was performed at 68°C for 18 hours. The hybridized
probes were visualized by an anti-DIG-alkaline phos-
phatase conjugate-catalyzed color reaction using BCIP (5-
bromo-4-chloro-3-indolylphosphate) and nitroblue tetra-
zolium salt (Boehringer Manheim, Germany).
Statistical analyses were performed by using the chi-
square and Fisher's exact tests with a significance level of
p < 0.05.BMC Cancer 2006, 6:115 http://www.biomedcentral.com/1471-2407/6/115
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Results
To analyze the coexistence of human papillomavirus infec-
tion and K-ras gene activation in colon carcinoma, we
investigated 53 tumor samples for the presence of HPV
infection (types 6, 11, 16, 18 and 33) and K-ras codon 12
and codon 13 mutations. Codon 12 mutations were
detected in 31 cases (58.5%) while fragments of the HPV
genome were found in 43 (81.2%) cases. K-ras gene codon
13 mutations were not observed in the tumor samples of
colon cancer patients. In 17 samples (32 %) genomic HPV
fragments were also detected in the corresponding adja-
cent normal tissue. K-ras codon 12 or codon 13 mutations
were not present in any of the normal tissue samples.
24 of 43 (55.8 %) HPV-positive samples and 7 of 10
(70%) HPV-negative samples analysed harbored a muta-
tion in codon 12 of the K-ras gene. HPV 18 and HPV 33
were the most frequent types (73.6% and 56.6%, respec-
tively). HPV 6, HPV 16, and HPV 11 were detected in 8, 5,
and 2 cases, respectively. HPV 18 was not detected in the
adjacent normal tissue samples. The most prevalent HPV
types in normal tissue were HPV 16 (15%) and HPV 11
(13.2%). The distribution of HPV types between the nor-
mal and tumor tissue was not statistically significant
except for HPV types 18 and 33 (p < 0.001).
Statistical analysis did not reveal an association between
the HPV infection and K-ras mutation (Table 1). When we
compared the frequencies of the K-ras mutations in high-
and low-risk HPV-positive samples we failed to detect any
correlation between the HPV type and K-ras mutation. We
also found no correlation between the presence of K-ras
codon 12 mutations and coinfection with more than one
HPV type (Table 2).
Discussion
The current genetic model for colon carcinogenesis
depicts sequential accumulation of mutations in specific
cancer-related genes, including APC, K-ras, and p53 that
drive the transition from normal epithelium to increasing
adenomatous dysplasia and finally to cancer [24,25]. Dur-
ing this process additional cofactors and modifications
may act to immortalize and transform the cells. A great
deal of evidence has shown that infection with specific
papillomaviruses may be involved in the pathogenesis of
malignant tumors at various body sites, including the
anogenital area, the upper respiratory and digestive tracts,
and the breast [15-17].
Numerous studies in the literature support the role of the
ras protein and HPV viruses and indicate their probable
cooperation in the pathogenesis of cervical neoplasias
[26-28]. Mazurek et al [29] have shown that the E7 onco-
protein cooperates with ras in cell transformation.
Directly binding to M2-PK and inducing its dimerization
it thereby restores nucleic acid synthesis and cell prolifer-
ation.
The role of the ras oncogene [7,30-35] and HPV infection
[36-38] in colorectal carcinomas has been investigated
separately by several authors. However, the association
between HPV infection and K-ras mutations has not been
elucidated in colon cancer, yet.
In this study we observed mutations in the K-ras gene in
58.5 % of the tumor samples. This mutation frequency is
slightly higher than the frequencies reported for the K-ras
gene by other investigators in colon cancer [30-35,39]. K-
ras mutations are thought to be an early event in colorec-
tal neoplasia [1] and are observed in 9–10 % of small ade-
nomas, in 40–50 % of large adenomas and in 40–65 % of
colon carcinomas [24]. However, in a study analyzing K-
ras mutations in four different series of colorectal cancer
patients a mutation rate of 64 % was found in MYH-asso-
ciated polyposis patients [39]. An even higher frequency
of K-ras mutations (72 %) has been reported by Conlin et
al [32], when colon cancer cases were grouped according
to tumor stage. This variability can be explained by the
Table 1: Distribution of the K-ras codon 12 mutations among samples infected with different types of HPV viruses.
Virus Type K-ras mutation No Mutation Total p
n%n%
HPV 6 3 75 1 25 4 0.207
H P V  1 1 15 015 02 1
H P V  1 6 55 644 49 0 . 6 4 1
HPV 18 22 59 15 41 37 0.106
HPV 33 15 52 14 48 29 0.592
No Virus 7 70 3 30 10 0.09
Table 2: K-ras codon 12 mutation frequency according to the 
HPV risk types.
HPV type K-ras mutation No mutation p
High risk 24 17 0.127
Low risk 16 14 0.611
Coinfection 7 3 0.09BMC Cancer 2006, 6:115 http://www.biomedcentral.com/1471-2407/6/115
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selection of the patients and the methods used to analyse
K-ras mutations. The studies mentioned above have
sequenced the entire ras gene while we have investigated
only the codon 12 and codon 13 mutations, which com-
prise 90% of the mutations in the ras gene [33] and 20–
50% of the mutations observed in the colon cancer [12-
14].
Bodaghi et al [37] reported that HPV infection is common
in patients with colorectal cancer with the most prevalent
type being HPV 16. However, the presence of HPV-DNA
in colon tissue remains controversial. Although earlier
studies [40,41] have failed to detect HPV-DNA in colon
biopsy samples, more recent reports suggest that infection
with HPV 16 and 18 may be etiologically associated with
some cases of colon cancer [38,42]. In our study infection
with HPV was observed in a significant proportion of the
tumor samples. The high risk HPV 18 was the most prev-
alent HPV type. Interestingly, none of the adjacent normal
tissue samples was positive for HPV 18. This observation
is consistent with a recent report [38]. Our findings sup-
port the possibility that HPV infection is involved in
colorectal carcinoma [36-38], as demonstrated by the fact
that high risk HPV-DNA is present with a high frequency
in malignant lesions [15,16].
Conclusion
Our results suggest that mutational activation of the K-ras
gene is common in colon carcinogenesis and infection
with HPV may represent an additional important early
step in the development of premalignant transformation.
Further studies incorporating larger sample sizes are nec-
essary to provide more definitive data on the potential
role of these factors in colon carcinogenesis.
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